Patient first clinical supply solution for your clinical trial

One of the challenges in clinical trials is patient recruitment and retention. To meet this challenge head-on, many BioPharma companies are embracing Direct-to-Patient Models, recognizing their potential to enhance patient enrollment and adherence.

IMP's robust supply chain platform is tailor-made to provide solutions for clinical trial logistics in the context of Direct-to-Patient Models. We understand the critical importance of accommodating investigational product requirements, including temperature monitoring, validated shippers, and user-friendly patient kits, all while adhering to the highest quality standards.

Effective and early planning is the key to mitigating the challenges associated with the Direct-to-Patient Model. IMP brings its specialized expertise to manage the logistics of the supply chain and address the unique requirements that arise in Direct-to-Patient studies.

Our Direct-to-Patient services include:
  • Transportation from our depot to the clinical site in accordance to GDP guidelines
  • Transportation from the clinical site to the patient home in accordance to GDP guidelines
  • Temperature monitoring throughout the drug poduct use cycle
  • Qualified vendor for clinical sites and sponsors
  • Kit design and packaging for patients ease of use
Putting Patients First: Facilitating Decentralized Clinical Trials by Delivering Personalized Care Directly to the Patient

Related Articles

The Use of Direct-to-Patient Methods in Decentralised Clinical Trials in Israel
The Use of Direct-to-Patient Methods in Decentralised Clinical Trials in Israel

Abstract: Direct-to-patient (DtP) methods in clinical trials have gained significant attention worldwide as they aim to improve patient access, engagement, and participation in research studies. This paper explores the status of DtP strategies in the context of clinical trials in Israel. It discusses the current landscape, challenges, benefits, and regulatory aspects of DtP initiatives in […]

Read more

Contact Us

    Back to top